🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07195604
Completed Phase 1

A Single Ascending Dose of HRS-2162 in Healthy Subjects

NCT07195604 · tracked via the Priya Life Science China tracker
Sponsor
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase
Phase 1
Started
2025-09-25
Last updated
2026-09-22

Condition(s) studied

Reversal of Neuromuscular Blockade

Investigational drug(s) / intervention(s)

HRS-2162Placebo

HRS-2162: HRS-2162

Placebo: Placebo

Study summary

The study is being conducted to evaluate the safety and tolerability of HRS-2162 injection in a single dose in healthy subjects, as well as the characteristics of PK/PD

Eligibility

Sex
ALL
Min age
18 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. The subjects voluntarily signed the informed consent form. 2. Applicants must be between 18 and 45 years old at the time of signing the informed consent form, and both men and women are eligible . 3. ASA classification is Grade I (only Parts Two and three) 4. Male weight ≥50 kg, female weight ≥45 kg, body mass index between 19 and 28 kg/m ². 5. Adopt efficient contraceptive measures Exclusion Criteria: 1. Those with a past or current clinical acute or chronic disease 2. Those with a history of hereditary bleeding or coagulation disorders or non-traumatic bleeding . 3. Those with a history of neuromuscular diseases or poliomyelitis 4. Those with a history of anesthesia complications. 5. Those whose laboratory test results during the screening period or baseline period exceed the normal range and have clinical significance 6. The blood pressure of the subjects was abnormal and was judged by the researchers to be of clinical significance 7. The subject has a history of severe systemic allergies for any reason. 8. The subjects took steroid hormone drugs within 7 half-lives or 14 days before administrationSmoke ≥5 cigarettes per day within 3 months prior to the study. 9. History of drug abuse. 10. Those who the researchers considered unsuitable for inclusion

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Sichuan Academy of Medical Sciences &Sichuan Provincial People's Hospital Chengdu Sichuan

More Fujian Shengdi Pharmaceutical Co., Ltd. trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07195604 on ClinicalTrials.gov ↗ ← All trials in China